Cognizant’s AI and industry expertise, combined with the NVIDIA BioNeMo generative AI platform, creates a strong foundation for improving outcomes in healthcare and life sciences.
teaneck new jersey, March 19, 2024 /CNW/ — Cognizant (NASDAQ: CTSH) is using the NVIDIA BioNeMo platform to solve complex drug discovery challenges in the life sciences industry, including increasing the productivity of the development process; We are advancing the application of generative AI (gen AI) technology using . New life-saving treatments will be brought to market faster.
Traditional drug discovery methodologies are process-intensive and require analyzing vast repositories of scientific literature and clinical data to uncover relevant insights. Furthermore, traditional methods are burdened with high costs and long development lifecycles, and are associated with high failure rates. By leveraging Gen AI technology, clinical researchers can quickly sift through extensive data sets, more accurately predict interactions between drug compounds, and create viable new drug development pathways.
“More than any other technological advance in recent decades, generative AI has the potential to revolutionize the way new medicines are researched, developed, and brought to market, making life-saving discoveries faster and smarter. , and make it more accessible to everyone,” he said. Anna Elango, Vice President of Core Technologies and Insights at Cognizant. “By working with NVIDIA, Cognizant can pave the way for our life sciences clients to realize this vision in a safe, responsible, and cost-effective manner.”
Cognizant leverages its deep expertise in life sciences and AI and NVIDIA’s pre-trained, industry-specific generative AI models, available as part of BioNeMo, to help clients build pre-trained models, state-of-the-art Our framework, API, provides clients with the quickest path to training and customizing enterprise models using their own data. This product aims to reduce manual intervention for data analysis and enable this without the need to write complex code or build or maintain infrastructure.
“Generative AI, enabled by the NVIDIA AI enterprise software platform, is driving the next wave of enterprise productivity improvements across industries.” Alvin Dacosta, Vice President, NVIDIA Global Consulting Partner Organization. “NVIDIA BioNeMo will enable Cognizant to provide life sciences clients with advanced, secure and reliable AI services to drive improved outcomes with custom drug discovery applications.”
Cognizant works with the world’s leading pharmaceutical, biotech and medical device companies, covering the entire life sciences value chain from research and development to digital health. By enabling a patient-centered approach and better interaction with healthcare professionals, this initiative will contribute to the industry’s ability to strengthen science, improve patient outcomes, and drive business value. Cognizant’s life sciences products support more than 120 global manufacturing lines and more than 18 million patients using the medical device company’s products.
Cognizant plans to collaborate with NVIDIA to pursue additional applications in areas such as manufacturing and automotive engineering. Here, Gen AI has the potential to increase productivity, optimize costs, and bring innovation to market faster. Cognizant will establish the NVIDIA AI Center of Excellence this year to further innovate with his NVIDIA technologies, including: NVIDIA Metropolis, NVIDIA Omniverse and the NVIDIA AI Enterprise platform for the benefit of clients in industries around the world.
About Cognizant
Cognizant (NASDAQ: CTSH) is architecting modern business. We help our clients modernize technology, reimagine processes, transform experiences, and stay ahead in a rapidly changing world. Together we will improve everyday life.See how www.cognizant.com Or @cognizant.
View original content to download multimedia: https://www.prnewswire.com/news-releases/cognizant-to-apply-generative-ai-to-enhance-drug-discovery-for- pharmaceutical-clients-with-nvidia-bionemo -302092208.html
source recognition
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/March2024/19/c9490.html
